SCHEMBL11944178

SCHEMBL11944178

CC(C)S(=O)(=O)N1CCN(c2cnn(-c3cccc(Cl)c3)c(=O)c2OC2CCN(C(=O)OC(C)(C)C)CC2)CC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NPBWR1 P48145 1/20 0.55
▸ MCHR1 Q99705 1/20 0.55
▸ MAPT P10636 5/20 0.52
▸ TP53 P04637 6/20 0.48
▸ POLB P06746 2/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.48
▸ LMNA P02545 2/20 0.44
▸ HPGDS O60760 1/20 0.44
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ PPARG P37231 1/20 0.43
▸ NCOA2 Q15596 1/20 0.43
▸ NCOA1 Q15788 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ NCOA3 Q9Y6Q9 1/20 0.43
▸ STS P08842 1/20 0.43
▸ GPR119 Q8TDV5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11944111 0.95 NPBWR1 (0.50) NPBWR1MCHR1MAPTTP53POLB
SCHEMBL11944075 0.93 MAPT (0.49) NPBWR1MCHR1MAPTTP53POLB
SCHEMBL11944288 0.91 MAPT (0.46) NPBWR1MCHR1MAPTTP53POLB
SCHEMBL11944201 0.91 POLB (0.46) NPBWR1MCHR1MAPTTP53POLB
SCHEMBL11944204 0.91 POLB (0.46) NPBWR1MCHR1MAPTPOLBCYP3A4
SCHEMBL11944328 0.90 GPR119 (0.44) NPBWR1MCHR1MAPTTP53POLB
SCHEMBL11944215 0.89 MAPT (0.49) NPBWR1MCHR1MAPTTP53POLB
SCHEMBL11944087 0.87 POLB (0.42) NPBWR1MCHR1MAPTTP53POLB
SCHEMBL11945207 0.87 POLB (0.47) NPBWR1MCHR1MAPTTP53POLB
SCHEMBL11944731 0.87 POLB (0.49) NPBWR1MCHR1MAPTPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA NPBWR1 4643/4885MCHR1 4513/4885MAPT 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback